Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00384358 · ClinicalTrials.gov registry record · Phase 2
Feasibility And Safety Study Of rhBMP-2/CPM For Hip Fractures
A Phase 2 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 108
- Enrollment target
NCT00384358 is a Phase 2 study that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 108 participants.
The verdict
NCT00384358, a Phase 2 study, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 108 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess the safety of administering rhBMP-2/CPM as an adjuvant to internal fixation in subjects with fractures of the proximal femur.
Interventions
- DRUG rhBMP-2/CPM
- OTHER surgical intervention alone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2006-12 |
| Est. Completion | 2010-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00384358
The ClinicalTrials.gov registry entry for NCT00384358 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which rhBMP-2/CPM is the first listed.
NCT00384358 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00384358 about?
NCT00384358 is a clinical study titled "Feasibility And Safety Study Of rhBMP-2/CPM For Hip Fractures". The primary objective of this study is to assess the safety of administering rhBMP-2/CPM as an adjuvant to internal fixation in subjects with fractures of the proximal femur.
What is the current status of trial NCT00384358?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 108 participants. The study started on 2006-12. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00384358?
The interventions under investigation include: rhBMP-2/CPM (DRUG), surgical intervention alone (OTHER).
Who is sponsoring clinical trial NCT00384358?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.